Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease
Top Cited Papers
Open Access
- 31 October 2006
- journal article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 4 (10), 1248-1254
- https://doi.org/10.1016/j.cgh.2006.06.025
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s diseaseClinical Gastroenterology and Hepatology, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology, 2004
- Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trialGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseThe New England Journal of Medicine, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 1997
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980